Recurrent Breast Cancer Completed Phase 2 Trials for Gefitinib (DB00317)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

IndicationStatusPhase
DBCOND0028640 (Recurrent Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00024154Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast CancerTreatment
NCT00057941Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast CancerTreatment